Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)
Abstract Introduction Definitive chemoradiotherapy has established the standard non-surgical treatment for locally advanced esophageal cancer. The standard dose of 50–50.4 Gy has been established decades ago and been confirmed in modern trials. The theorical advantage of better local control and tec...
Main Authors: | Hongcheng Zhu, Qiufang Liu, Hao Xu, Miao Mo, Zezhou Wang, Kui Lu, Jialiang Zhou, Junqiang Chen, Xiangpeng Zheng, Jinjun Ye, Xiaolin Ge, Honglei Luo, Qi Liu, Jiaying Deng, Dashan Ai, Shengnan Hao, Junhua Zhang, I Hsuan Tseng, Shaoli Song, Yun Chen, Kuaile Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-07-01
|
Series: | Radiation Oncology |
Online Access: | https://doi.org/10.1186/s13014-022-02099-y |
Similar Items
-
Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
by: Dashan Ai, et al.
Published: (2023-02-01) -
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trialResearch in context
by: Dashan Ai, et al.
Published: (2024-03-01) -
Dose escalation guided by 18F-FDG PET/CT for esophageal cancer
by: Bingjie Fan, et al.
Published: (2021-06-01) -
Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020
by: Hongcheng Zhu, et al.
Published: (2023-04-01) -
Lymphocyte recovery from radiation-induced lymphopenia in locally advanced esophageal squamous cell carcinoma: correlations with prognosis and lymphocyte-related organs
by: Ihsuan Tseng, et al.
Published: (2023-10-01)